https://www.selleckchem.com/pr....oducts/hmpl-504-azd6
The patient with a clinical benefit response received a total of 27 cycles and the two patients with stable disease were taken off the study due to progression after four and six cycles, respectively. Of the 10 inevaluable patients, nine received ≤1 cycle due to clinical deterioration and one had an anaphylactic reaction. One patient had a grade 3 rash which resolved after a delay in treatment. No dose reduction was reported. In this cohort, single agent therapy with cetuximab was well tolerated and had a 15% clinical
Like
Comment
Share
